Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening
- PMID: 28753431
- DOI: 10.1016/j.cell.2017.07.005
Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening
Abstract
Elucidation of the mutational landscape of human cancer has progressed rapidly and been accompanied by the development of therapeutics targeting mutant oncogenes. However, a comprehensive mapping of cancer dependencies has lagged behind and the discovery of therapeutic targets for counteracting tumor suppressor gene loss is needed. To identify vulnerabilities relevant to specific cancer subtypes, we conducted a large-scale RNAi screen in which viability effects of mRNA knockdown were assessed for 7,837 genes using an average of 20 shRNAs per gene in 398 cancer cell lines. We describe findings of this screen, outlining the classes of cancer dependency genes and their relationships to genetic, expression, and lineage features. In addition, we describe robust gene-interaction networks recapitulating both protein complexes and functional cooperation among complexes and pathways. This dataset along with a web portal is provided to the community to assist in the discovery and translation of new therapeutic approaches for cancer.
Keywords: CCLE; DRIVE; RNA interference; cancer dependency; functional genomics; synthetic lethality.
Copyright © 2017 Elsevier Inc. All rights reserved.
Similar articles
-
Identification of synthetic lethality of PRKDC in MYC-dependent human cancers by pooled shRNA screening.BMC Cancer. 2014 Dec 13;14:944. doi: 10.1186/1471-2407-14-944. BMC Cancer. 2014. PMID: 25495526 Free PMC article.
-
Defining a Cancer Dependency Map.Cell. 2017 Jul 27;170(3):564-576.e16. doi: 10.1016/j.cell.2017.06.010. Cell. 2017. PMID: 28753430 Free PMC article.
-
Partial gene suppression improves identification of cancer vulnerabilities when CRISPR-Cas9 knockout is pan-lethal.Genome Biol. 2023 Aug 23;24(1):192. doi: 10.1186/s13059-023-03020-w. Genome Biol. 2023. PMID: 37612728 Free PMC article.
-
Current views on inducing synthetic lethal RNAi responses in the treatment of cancer.Expert Opin Biol Ther. 2016;16(2):161-72. doi: 10.1517/14712598.2016.1110141. Epub 2015 Dec 2. Expert Opin Biol Ther. 2016. PMID: 26630128 Review.
-
RNAi and HTS: exploring cancer by systematic loss-of-function.Oncogene. 2004 Nov 1;23(51):8392-400. doi: 10.1038/sj.onc.1208217. Oncogene. 2004. PMID: 15517021 Review.
Cited by
-
Aloperine Suppresses Cancer Progression by Interacting with VPS4A to Inhibit Autophagosome-lysosome Fusion in NSCLC.Adv Sci (Weinh). 2024 Aug;11(31):e2308307. doi: 10.1002/advs.202308307. Epub 2024 Jun 21. Adv Sci (Weinh). 2024. PMID: 39166458 Free PMC article.
-
BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR Dependency.Cancer Res. 2020 Sep 15;80(18):3841-3854. doi: 10.1158/0008-5472.CAN-20-1744. Epub 2020 Jul 20. Cancer Res. 2020. PMID: 32690724 Free PMC article.
-
INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas.Nat Cancer. 2024 Mar;5(3):481-499. doi: 10.1038/s43018-023-00710-z. Epub 2024 Jan 17. Nat Cancer. 2024. PMID: 38233483 Free PMC article.
-
Synthetic lethality as an engine for cancer drug target discovery.Nat Rev Drug Discov. 2020 Jan;19(1):23-38. doi: 10.1038/s41573-019-0046-z. Epub 2019 Nov 11. Nat Rev Drug Discov. 2020. PMID: 31712683 Review.
-
Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant Cancers.Clin Cancer Res. 2019 Jan 1;25(1):346-357. doi: 10.1158/1078-0432.CCR-18-1129. Epub 2018 Sep 26. Clin Cancer Res. 2019. PMID: 30257981 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
